for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

DelMar Pharmaceuticals Inc

DMPI.OQ

Latest Trade

0.49USD

Change

0.00(+1.01%)

Volume

8,556

Today's Range

0.48

 - 

0.50

52 Week Range

0.40

 - 

6.95

As of on the NASDAQ ∙ Minimum 15 minute delay

Latest Developments

DelMar Says During Audit For Year-Ended June 30, 2019, Material Weakness In Operating Effectiveness Of Internal Controls Over Financial Reporting Was Identified

Oct 1 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR- DURING AUDIT FOR YEAR-ENDED JUNE 30, 2019, MATERIAL WEAKNESS IN OPERATING EFFECTIVENESS OF INTERNAL CONTROLS OVER FINANCIAL REPORTING WAS IDENTIFIED.DELMAR - WEAKNESS RELATED TO INADEQUATE SEGREGATION OF DUTIES OVER AUTHORIZATION, REVIEW & RECORDING OF TRANSACTIONS, AS WELL AS FINANCIAL REPORTING.DELMAR PHARMACEUTICALS INC - ON SEPT. 30, E&Y RESIGNED AS CO'S INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM..

DelMar Pharmaceuticals Files For Offering 6 Mln Shares Of Common Stock

Aug 1 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS INC FILES FOR OFFERING 6 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING.

DelMar Pharmaceuticals Enrolls First Patient In The Recently-Approved Adjuvant Setting Arm Of Phase 2 Study Of VAL-083

July 24 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ENROLLS FIRST PATIENT IN THE RECENTLY-APPROVED ADJUVANT SETTING ARM OF PHASE 2 STUDY OF VAL-083 FOR THE TREATMENT OF MGMT-UNMETHYLATED GLIOBLASTOMA MULTIFORME.DELMAR PHARMACEUTICALS INC - DELMAR IS ACTIVELY ENROLLING PATIENTS FOR BOTH TRIAL ARMS OF CLINICAL STUDY AT MDACC..DELMAR PHARMACEUTICALS INC - CONDUCTING A PHASE 2 CLINICAL STUDY OF VAL-083 AS FIRST LINE TREATMENT FOR GBM IN COMBINATION WITH RADIOTHERAPY IN CHINA.

Delmar Pharmaceuticals Files Prospectus Relates To Resale By Selling Stockholders Of Up To 760,500 Shares Of Co's Common Stock - SEC Filing

June 25 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS FILES PROSPECTUS RELATES TO RESALE BY SELLING STOCKHOLDERS OF UP TO 760,500 SHARES OF CO'S COMMON STOCK - SEC FILING.

Delmar Provides Clinical Update On Val-083 From Ongoing 1st & 2nd-Line Trials In Patients With MGMT-unmethylated Glioblastoma

June 3 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PROVIDES CLINICAL UPDATE ON VAL-083 FROM ONGOING FIRST- AND SECOND-LINE TRIALS IN PATIENTS WITH MGMT-UNMETHYLATED GLIOBLASTOMA AT A KEY OPINION LEADER FORUM DURING THE AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING.DELMAR PHARMACEUTICALS INC - FOURTEEN OF EIGHTEEN PATIENTS WERE STILL ALIVE AT DATA CUT-OFF DATE.DELMAR PHARMACEUTICALS INC - AS OF MAY 17, 2019, EIGHTEEN PATIENTS HAVE BEEN ENROLLED IN TRIAL.DELMAR PHARMACEUTICALS INC - TRIAL IS DESIGNED TO ENROLL UP TO 30 PATIENTS.DELMAR PHARMACEUTICALS INC - TWO PATIENTS HAVE NOT BEEN ON STUDY LONG ENOUGH TO REACH FIRST ASSESSMENT, AND 1 PATIENT DIED BEFORE FIRST ASSESSMENT.DELMAR - ALSO UPDATED ON ONGOING SECOND-LINE PHASE 2 CLINICAL STUDY OF VAL-083 IN PATIENTS WITH MGMT-UNMETHYLATED, BEVACIZUMAB-NAÏVE RECURRENT GBM.

Delmar Pharmaceuticals Announces 1-For-10 Reverse Stock Split

May 7 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES 1-FOR-10 REVERSE STOCK SPLIT.DELMAR PHARMACEUTICALS - REVERSE STOCK SPLIT EFFECTIVE FOR TRADING PURPOSES AS OF COMMENCEMENT OF TRADING ON MAY 8, 2019.

Delmar Pharmaceuticals Announces Second Quarter 2019 Results

Feb 12 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS ANNOUNCES SECOND QUARTER FISCAL YEAR 2019 FINANCIAL RESULTS.Q2 LOSS PER SHARE $0.08.DELMAR PHARMACEUTICALS - EXPECTS TO HAVE CASH AVAILABLE TO FUND PLANNED OPERATIONS INTO MIDDLE OF CALENDAR 2019.

Delmar Pharmaceuticals Appoints Oppenheimer & Co Inc As Strategic Advisor

Sept 4 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR PHARMACEUTICALS APPOINTS OPPENHEIMER & CO. INC. AS STRATEGIC ADVISOR.DELMAR PHARMACEUTICALS - FIRM WILL WORK ON BEHALF OF CO TO MANAGE EXPLORATION & EVALUATION OF RANGE OF STRATEGIC OPPORTUNITIES.

DelMar Says Robert Hoffman Appointed Chairman Of The Board

June 7 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR SAYS ON JUNE 2, ERICH MOHR, CHAIRMAN OF BOARD NOTIFIED CO THAT HE WOULD STEP DOWN FROM ROLE AS CHAIRMAN, MEMBER OF CO'S BOARD - SEC FILING.SAYS ROBERT E. HOFFMAN APPOINTED CHAIRMAN OF THE BOARD.

Delmar Appoints Saiid Zarrabian Full-Time President And CEO

May 22 (Reuters) - DelMar Pharmaceuticals Inc <DMPI.O>::DELMAR APPOINTS SAIID ZARRABIAN TO FULL-TIME PRESIDENT AND CEO.DELMAR PHARMACEUTICALS - ZARRABIAN HAD PREVIOUSLY SERVED AS INTERIM PRESIDENT AND CEO SINCE NOVEMBER 2017.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up